Drugs / Exicorilant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03877952 | Sep → Nov 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03335956 | Sep 2017 → May 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03437941 | Feb 2018 → Oct 2021 | prostate carcinoma | Corcept Therapeutics | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exicorilant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03437941 ↗ |
| Known as | CORT125281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03877952 ↗ |
| Action | Inhibit | “Exicorilant is a selective glucocorticoid receptor (GR) antagonist.” NCT03437941 ↗ |
| Modality | Small molecule | — CHEMBL4089731 ↗ |
| Route | Oral | “CORT125281 is supplied as capsules for oral dosing” NCT03335956 ↗ |